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Significant advances have been made in methods to
analyze genomes and transcriptomes of single cells,
but to fully define cell states, proteins must also be
accessed as central actors defining a cell’s pheno-
type.Methods currently used to analyze endogenous
protein expression in single cells are limited in spec-
ificity, throughput, or multiplex capability. Here, we
present an approach to simultaneously and specif-
ically interrogate large sets of protein and RNA tar-
gets in lysates from individual cells, enabling investi-
gations of cell functions and responses. We applied
our method to investigate the effects of BMP4, an
experimental therapeutic agent, on early-passage
glioblastoma cell cultures. We uncovered significant
heterogeneity in responses to treatment at levels of
RNA and protein, with a subset of cells reacting in a
distinctmanner to BMP4.Moreover, we found overall
poor correlation between protein and RNA at the
level of single cells, with proteins more accurately
defining responses to treatment.
INTRODUCTION
The need to understand differences within cellular communities
and the nature of heterogeneous cellular responses have
prompted development of efficient methods for genomic and
transcriptomic analysis at the level of single cells (Macaulay
and Voet, 2014; Patel et al., 2014). In order to better understand
functional properties of cells, these molecular genetic tech-
niques need to be complemented by high-performance and
high-throughput single-cell protein analyses. Current methods
to study endogenous protein expression in single cells tend
to be limited in throughput or multiplex capability (Bendall
et al., 2011; Sta˚hlberg et al., 2012; Ullal et al., 2014; Yu et al.,
2014). Moreover, unlike the state of the art for measuring pro-
teins in e.g., plasma, currently available single cell protein as-380 Cell Reports 14, 380–389, January 12, 2016 ª2016 The Authorssays rely on target recognition by single antibodies, thus
limiting detection specificity.
Here, we present a procedure to simultaneously interrogate
large sets (96) of both RNA and protein targets in single-cell ly-
sates to investigatecell functionsand responses. Inourapproach,
single isolatedcells are lysedanddivided for separateRNAorpro-
tein analysis (Figure 1A). Proteins are probed using a homoge-
neous affinity-based proximity extension assay (PEA) that targets
proteins using pairs of antibodies conjugated with oligonucleo-
tides whose free 30 ends are pairwise complementary (Assarsson
et al., 2014). When a cognate antibody pair binds a target protein,
the attached oligonucleotides are brought in proximity andcanbe
extendedbypolymerization to create an amplifiable DNA reporter
molecule, which is subsequently quantified by high-throughput
real-timePCR. The requirement for pairwise protein detection en-
sures sandwich immunoassay-quality protein detection. A multi-
plex readout is achieved by decoding extension-generated DNA
reporters by real-timePCRusing primer pairs specific for cognate
pairs of antibody conjugates. Transcripts are probed using com-
mercial TaqMan Gene Expression Assays using a previously
described method (Dalerba et al., 2011).
We applied the approach above to characterize the effects of
treatment with bone morphogenetic protein 4 (BMP4) on early-
passageU3035MGcells, derived fromapatientwithglioblastoma
and grown under neural stem cell conditions. BMP4, a cytokine
belonging to the transforming growth factor b (TGF-b) superfam-
ily, is of interest as a potential therapeutic agent in glioblastoma
(Duggal et al., 2013). It is believed to reduce numbers of tumor-
initiating precursors through induction of astroglial differentiation,
thereby potentially limiting tumor propagation and therapeutic
resistance (Bao et al., 2006; Piccirillo et al., 2006). During initial
screening, U3035MG displayed partial resistance to BMP4 (not
shown), motivating a search for factors that contribute to the
observed phenotype among all or some of the cells.
RESULTS
Protein and RNA Assay Validation
To construct a multiplex PEA panel for probing cell states, tar-
geting cancer and neuro-oncology pathways of relevance in
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Figure 1. Experimental Approach and Validation
(A) Illustration of the experimental approach. Single cells are isolated by FACS and lysed immediately. Cell lysates are split for subsequent protein and RNA
analysis by PEA and gene-targeted TaqMan assays, respectively.
(B) Standard curves of sorted 1,000, 100, and 10 U3035MG cells plus no cell control (blank) for select PEA assays. The circle and triangle data points represent
biological replicates. The red horizontal bar denotes the mean background value, whereas the dashed lines are the mean ± 3 SD. y axis values represent
extension control normalized Cq values. See also Figure S1.
(C) Coefficient of variation analysis of n = 40 split U3035MG single cells, where both halves were analyzed with the same PEA single cell protein panel. The
coefficient of variation of each assay is plotted as a function of the number cells, out of a total 40 cells, in which the assay generated a detectable signal cells (top
left). The top right panel shows the correlation between themean values for each protein assay, comparing cell half 1 and 2 for each cell. The bottom panel shows
the correlation coefficients between each of the two lysate aliquots, calculated for each cell across all assays.glioblastoma, we selected polyclonal antibodies raised against
all or a significant portion of the proteins of interest. After vali-
dating assay sensitivity and specificity, a panel of 75 PEA assays
was selected with sensitivity down to ten cells or fewer and no
evidence of cross-reactivity in our cell model of interest (Fig-
ure 1B; Table S1; Figure S1).
RNA was probed using commercial TaqMan Gene Expression
Assays as in a previously described approach (Dalerba et al.,
2011). Eighty-two assays were selected to complement the glio-
blastoma single-cell protein panel in capturing BMP signaling, its
interaction with other pathways (e.g., WNT or TGF-b), and
cellular processes such as differentiation, proliferation, and
apoptosis, expected to be affected by BMP4 (Piccirillo et al.,C2006). Twenty-two of the TaqMan assays targeted transcripts
for genes whose protein products were included in the protein
panel permitting evaluation of RNA-protein correlations (see Ta-
ble S1 for a list of assays). The final combined RNA and protein
panel members had high coverage of gene products involved
in major cancer pathways, focal adhesion, cell cycle, apoptosis,
and cell development (as identified via KEGG and Reactome
Pathways as well as Gene Ontology [GO] terms). The details
are listed in Table S1.
To assess the precision of the single-cell protein assays, we
sorted 40 individual U3035MG cells using fluorescence-acti-
vated cell sorting (FACS). These cells are distinct from the cells
sorted and analyzed for BMP4 response. Upon lysis, two halvesell Reports 14, 380–389, January 12, 2016 ª2016 The Authors 381
of each lysate were probed separately with the glioblastoma sin-
gle-cell protein panel. We then calculated the coefficient of vari-
ation (CV) per cell and per assay, excluding samples and targets
with no detectable signals. The mean CV across assays was
12.2% (interquartile range [IQR], 9.5%–13.4%). When the
percent CV is plotted against the number of single cells for which
a signal over background was detected in a given assay, the CV
is stable for assays where the molecules were detected in more
than five single cells (Figure 1C, top left panel). In addition, the
Spearman correlation between the mean Ct values obtained
for each assay in all cells revealed a rank correlation coefficient
of 0.999, demonstrating excellent reproducibility (Figure 1C,
top right). Furthermore, the correlation for the same measure-
ments in the two halves of each of the 40 cells for all assays
had an average Spearman rank correlation coefficient of 0.985
(min = 0.9636, max = 0.9941) (Figure 1C, bottom). We similarly
determined the reproducibility of RNA detection. Split single-
cell lysates from cell lines MCF-7 and Hs578T were probed
with 12 different TaqMan assays, revealing a mean CV across
assays of 26% (IQR, 14.5%–35.1%). In addition to probing split
MCF-7 or Hs578T single cells, we also calculated the CV% for
aliquots of lysates prepared from 1,000 (PEA only), 100, or 10
MCF-7 or Hs578T cells. We conclude that the CV% was satis-
factory across cell numbers for both the PEA or TaqMan probes.
We note, however, that the CV%was stable across cell numbers
interrogated with the PEA assays, but the CV% increased with
decreasing cell number with the TaqMan assays, although they
remained within an acceptable range (mean CV% for 100 cells =
13, for 10 cells = 18, and for single cells = 26). We thus conclude
that our assays were reliable and reproducible, allowing accu-
rate measurement of protein and RNA levels in single-cell
lysates.
Agreement between Bulk Population and Single Cells
In order to evaluate the agreement of the signals detected in sin-
gle cells with results from bulk samples, we sorted two sets of
150 cells from the same population sorted for single-cell anal-
ysis. There was good agreement between the mean expression
across single cells and that observed for pooled cells (Pearson’s
r = 0.68; Figure 2A). Five proteins with poor correlation between
average single and pooled cells (PLCG1, FAS, SMAD1, EGFR,
and ITGA1) were all expressed close to the limits of detection
in single cells (0.5 ddCq over background), and the differences
between treated and untreated cells in the pooled sample were
small.
Correlation of RNA and Protein Expression
Across all single cells, the coefficients of determination (R2) be-
tween protein and RNA levels were on average 0.04 (min = 0,
max = 0.35) for the RNAs and proteins encoded by the same
genes (Figure S2). This suggests that for most gene products,
only a small portion of the variation of protein levels can be ex-
plained bymeasuringmRNA levels in single cells. The correlation
is much lower than what has been reported for experiments per-
formed on populations of cells (Jovanovic et al., 2015; Schwan-
ha¨usser et al., 2011). In pools of cells, protein and mRNA levels
are averaged over large numbers of cells, ignoring any cell-to-
cell variation. Burst-like transcription and generally shorter382 Cell Reports 14, 380–389, January 12, 2016 ª2016 The Authorshalf-lives for RNA may conspire to render RNA levels less accu-
rate indicators of cell states at the single-cell level, compared to
the more stable proteins whose levels may need to be main-
tained to enact the various functions of cells (Raj and van Oude-
naarden, 2009; Schwanha¨usser et al., 2011).
Of the protein-RNA pairs that were significantly correlated us-
ing the measure Pearson’s r (p < 0.001; CAV1, GFAP, PLAU,
PXN, SOD1, and SOX2), all were positively correlated, but they
displayed different dynamics of co-expression (Figure 2B). The
mesenchymal marker PLAU (Verhaak et al., 2010) (Pearson’s
r = 0.16) was detected in most cells at the level of protein, but
only a small fraction of cells had detectable RNA expression.
That is consistent with a model where RNA levels are transient
whereas protein levels are maintained for longer periods of
time as required to maintain cellular functions (Schwanha¨usser
et al., 2011).
SOD1 RNA and protein displayed a strong correlation (Pear-
son’s r = 0.45–0.52 across time points; Figure 2B), with two
notable observations. First, the distribution of RNA expression
was similar whether or not the cells had been treated with
BMP4, yet protein expression differed between treatment
groups. Second, the distribution of protein expression was
bimodal in the BMP4-treated cells, with one group of cells (n =
20) displaying no detectable protein but clear RNA expression.
Moreover, SOD1PROTEIN was strongly correlated withMIFPROTEIN
(Pearson’s r = 0.79), but not withMIFRNA (Pearson’s r = 0.18). The
cells that expressed no detectable SOD1PROTEIN were also
devoid of MIFPROTEIN, suggesting tight co-regulation of these
proteins (Israelson et al., 2015).
BMP4 Treatment and Single-Cell Analysis
BMP4-treated U3035MG cells grown under neural stem cell
conditions maintained persistent proliferation in the presence
of BMP4, albeit at a reduced rate compared to untreated con-
trols (doubling time 2.5 days rather than 1.8 days) (Figure S3).
Other cell lines derived from patients with glioblastoma dis-
played a heterogeneous response to BMP4, but with signifi-
cantly reduced cell division in the majority of lines tested (data
not shown).
We analyzed single U3035MG cells before treatment (79 cells
analyzed) and 6 days after initiation of BMP4 treatment, a time
point when control cells (62 cells analyzed) were not confluent,
and when BMP4-resistant treated cells (69 cells analyzed) had
expanded to constitute a significant fraction of the treated cell
population. In total, 210 single cells were monitored for RNA
and protein levels (Table S2). The RNA and protein data for
U3035MG were processed for quality control (QC) filtering and
normalization (see Experimental Procedures). Of the 75 and 82
proteins and transcripts, respectively, that were assayed, 46
PEA assays and 23 TaqMan assays were positive in greater
than 50% of the cells interrogated.
The first dimension (PC1) of a principal component analysis
(PCA) of normalized, combined RNA and protein datasets from
day 6 clearly separated the control and BMP4-treated cells,
whereas the second dimension (PC2) captured variation present
within each of the groups (Figure 3A; Table S3). Hierarchical clus-
tering using gene products correlated with PC1 and PC2 (p <
0.001) correctly grouped treated and control cells (Figure 3B),
AB
Figure 2. Analysis of Agreement between Aver-
ages of Single Cells and a Bulk Population Sam-
ple and Single-Cell RNA-Protein Correlations
(A) Plot of the delta values (6d Control – 6d BMP4) for the
means from the single cells (x axis) or the population
controls (n = 150 cells) (y axis) sorted at the same time as
the single cells (Pearson’s r = 0.68). Gene products that
disagree between the average single and bulk controls
are in bold.
(B) Correlation plots between RNA and protein levels for
selected analytes in all single cells belonging to the 0-hr
untreated (green), day-6 untreated (red), and day-6
BMP4-treated (yellow) populations. Distributions of
protein and RNA levels are shown as ticks on the y and
x axes respectively.
See also Figure S2.
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with both RNA and protein contributing to the distinction be-
tween the two groups. We also detected clear subclusters
among both the control and BMP4-treated cells, highlighting sig-
nificant heterogeneity within the cell line (Figure 3A and B). Anal-
ysis inclusive of the 0-hr untreated cells was comparable to the
day-6-only analysis, with a clear distinction between untreated
and treated groups, and the 0-hr and day-6 controls clearly over-
lapping (Figure S3).
Although the U3035MG cells proved largely refractory to the
antiproliferative effect of BMP4 treatment (Figure S3), the cells
exhibited clear activation of the known BMP4 response gene
products ID1RNA and ID2RNA (Lasorella et al., 2014; Miyazono
and Miyazawa, 2002), and a large fraction of cells also had
increased expression of ID3RNA (Lasorella et al., 2014; Miyazono
andMiyazawa, 2002), SNAI1RNA (Savary et al., 2013), SMAD6RNA
(Imamura et al., 1997), and SMAD9RNA (Tsukamoto et al., 2014)
(Figures 3B and 3C). The results strongly suggest that the
BMP4 pathway was activated in all treated cells. We further
observed a decrease of the neural stem cell markers SOX2RNA,
SOX2PROTEIN, and NESRNA, as well as EPHA2PROTEIN (Miao
et al., 2015). Nonetheless, there were surprisingly few changes
in the proportion of cells expressing the astrocyte markers
GFAPRNA and GFAPPROTEIN or in their overall levels of expres-
sion, consistent with the observation that BMP4 failed to induce
terminal differentiation. The only cell marker detectable in an
increased number of cells upon treatment was the neuronal
marker TUBB3RNA (a change from 8% to 30% detectable cells)
(Figure 3C). A marginal increase of TUBB3PROTEIN upon BMP4
exposure was also demonstrated by flow cytometry using day-
6 control and BMP4-treated U3035MG cells (Figure S3). These
results suggest that a decrease in stemness, as reflected by
the decreased expression of SOX2/NES, was accompanied in
at least a subset of cells by differentiation toward a neuronal
fate, rather than the expected astrocyte-like fate (Piccirillo
et al., 2006). This broad differentiation potential is in agreement
with recent work showing that BMP4-treated glioma stem cell-
enriched cell linesmade either an astrocytic or a neuronal lineage
choice, depending on specific endogenous or exogenous fac-
tors (Videla Richardson et al., 2015).
The combined protein and RNA analysis identified clear differ-
ences between treated and untreated cells, but we were also
interested in possible heterogeneity within the groups of treated
or untreated cells. Hierarchical clustering separated both treated
and untreated cells in two subsets each (Figures 3A and 3B). The
two subpopulations of treated cells primarily differed in their
expression of the proliferation marker MKI67RNA (Whitfield
et al., 2006) and the cell-cycle regulators MELKRNA, FOXM1RNA
(Joshi et al., 2013), and AURKBPROTEIN (Whitfield et al., 2006)
(Figure 3C). Cells expressing high levels of proliferation markers
also exhibited significantly higher levels SMAD6RNA, a negative
regulator of BMP4 signaling (Imamura et al., 1997). The same
cells also had higher expression of a number of genes associ-
ated with a mesenchymal signature, specifically VIMRNA,
PLAUPROTEIN, SERPINE1PROTEIN, and TNCPROTEIN (Carro et al.,
2010; Phillips et al., 2006; Verhaak et al., 2010). Interestingly,
the extracellular matrix protein TNC can influence normal neural
stem cell development by modulating sensitivity to FGF2 (posi-
tively) and BMP4 (negatively) (Garcion et al., 2004). Using flow384 Cell Reports 14, 380–389, January 12, 2016 ª2016 The Authorscytometry, we confirmed that TNCPROTEIN is increased in
response to BMP4 and that its expression is enhanced in a sub-
set of proliferation-positive BMP4-treated cells (Figure S3).
Together, these results suggest that despite active signaling
through the BMP4 pathway, a subset of treated cells partially
escape the effects of BMP4 to maintain a proliferative state.
An avenue for further investigation using a still larger set of tran-
scripts and proteins is whether the cells also display a shift to-
ward a mesenchymal phenotype (Verhaak et al., 2010).
Relative Ability of RNA and Protein Expression Data to
Distinguish Treated and Untreated Cells
To examine whether either RNA or protein levels better reflected
the effects of BMP4 treatment, we performed PCA separately on
the 22 gene products analyzed both at levels of RNA and protein
(Figure 4). A combination of the first two principal components
for protein and RNA measurements, explaining 25.4% and
22.5% of the variance, respectively, was used as a basis for
receiver-operating characteristics (ROC) analysis of treated
versus untreated cells (see Experimental Procedures) (Figure 4).
The protein measurements accurately distinguished cells ac-
cording to whether they had been treated with BMP4 or not
with an area under the curve (AUC) of 0.99, whereas the corre-
sponding AUC for RNA measurements was lower at 0.87. To
ensure that the better distinction between treated and untreated
cells for protein rather than RNA measurements was not limited
to the first two principal components, we performed the same
type of analysis using the principal components from 1 to 30
for both protein and RNA. The results of this analysis are ex-
hibited in Figure S4 and demonstrate that proteins consistently,
albeit marginally, outperformed RNA in distinguishing treated
from untreated cells. For example, the AUC increased to 1.0
and 0.95 for protein and RNA, respectively, when the first three
principal components were included in the analysis. We note
that combined protein and RNA gave AUC values higher than
those observed when protein and RNA were used separately
(Figure S4).
DISCUSSION
We report the development of a precise approach to simulta-
neously quantify large numbers of RNA and proteins mole-
cules in single cells. Our method demonstrates so far the
highest degree of multiplexing for protein analysis in single
cells. Moreover, the method can be further extended, both
on the level of protein and RNA. Protein detection is currently
limited only by the selected microfluidic readout (96plex), while
it could be possible to record even more proteins and tran-
scripts levels through next-generation sequencing (Darmanis
et al., 2010). It has been shown previously that the perfor-
mance of proximity-based assays does not deteriorate with
increased multiplexing, in contrast to other protein assays
dependent on recognition by pairs of antibodies (Darmanis
et al., 2010). Furthermore, the protein analysis is compatible
with established single-cell RNA-sequencing (RNA-seq) proto-
cols (Picelli et al., 2014), thus allowing the analysis of whole
transcriptomic signatures along with large numbers of protein
molecules.
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Figure 3. Analysis of BMP4 Response in Glioblastoma Patient Cell Line U3035MG
(A) PCA (left) and gene vector (right) plots for PC1 and PC2 for day-6 untreated and BMP4-treated cells, using combined normalized RNA and protein data. For the
PCA plot, values for each marker in individual cells are reflected on a scale from blue to red. The colors and numbers at the top of the heatmap correspond to
(legend continued on next page)
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Figure 4. Distinction of Treated and Untreated Cells Using RNA or
Protein Expression Data
PCA plots of BMP4 treated (yellow) and untreated cells (brown) at day 6 using
expression of the same 22 genes, measured at the level of RNA (A) or protein
(B), illustrating the relative ability of protein and RNA analyses to correctly
identify whether cells had been treatedwith BMP4 or not. Insets show receiver-
operating characteristic (ROC) curves derived by performing linear discrimi-
nant analysis of the first two principal components. AUC, area under the curve.
See also Figure S4 for analysis including more principal components.Using combined RNA and protein data for individual cells, we
demonstrated significant heterogeneity within populations of a
low-passage cell culture derived from a patient with glioblas-
toma multiforme and grown under neural stem cell conditions.subclusters identified through the hierarchical clustering analysis shown in (B) wit
and subclusters 3 (turquoise) and 4 (purple) belonging to the day-6 BMP4-treated
plot, vectors illustrate the ten most significant variables, measured at the level of R
the first two principal components. The vector lengths represent the extent of co
(B) Hierarchical clustering and heatmap of factors significantly (p < 0.001) assoc
(C) Boxplots of select RNA or protein factors divided by subcluster. Subclusters a
values subtracted from the normalized mean background  2*SD of the mean b
See also Figure S3.
386 Cell Reports 14, 380–389, January 12, 2016 ª2016 The AuthorsThe expression pattern accurately distinguished control and
BMP4-treated cells. Furthermore, we demonstrated evidence
that RNA and protein data contribute distinct information in
defining cell states. In our model, protein expression was
marginally better at defining group membership. This difference
could in part reflect that protein levels are more stable over time
than RNA expression, as previously reported (Munsky et al.,
2012; Schwanha¨usser et al., 2011). The greater technical noise
in the assays employed here to measure RNA versus protein
abundance may also have contributed to this effect. However,
considerably more information is available via single-cell RNA-
seq than what can be obtained by measuring less than hundred
proteins as shown herein, compensating for any greater vari-
ability of RNA expression. Nonetheless, as we demonstrate in
this study, protein and RNA information can be used in a comple-
mentary way, and protein-level measurements may have a spe-
cial value in analyses of cell states such as the activation status
of signaling pathways as reflected in protein modifications and
interactions.
Glioblastomamultiforme is a devastating disease, and despite
aggressive conventional treatment, including surgical resection
followed by radio- and chemotherapy, tumors often relapse. A
major obstacle for efficient treatment is the intratumoral hetero-
geneity of the disease, motivating single-cell studies (Patel et al.,
2014; Sottoriva et al., 2013). In this study, we identified distinct
BMP4 treatment responses, highlighting a subset of cells that
appeared to escape the differentiating effect of BMP4 and failing
to become post-mitotic. These results reveal a need for better
understanding of the BMP4 effector pathways in cancer, and
they temper the prospects of BMP4 as a therapeutic agent in
glioblastoma multiforme. The investigation supports a role for
single-cell studies at levels of RNA and protein to identify pheno-
typic variation among subpopulations of cells, as an aide to
explore cellular responses, for prognostics, and to design
personalized treatment (Patel et al., 2014).
EXPERIMENTAL PROCEDURES
Design of Panels of Proximity Extension Assays
We annotated a list of 1,100 polyclonal antibodies from R&D Systems and Cell
Signaling directed against proteins of relevance for known cancer pathways,
cell states, and neuro-oncology and available without additives and at a suffi-
cient concentration for conjugation. To design a panel to investigate cell
states, we selected 11 GO Slim categories (cumulative versions of the GO cat-
egories containing a subset of the whole GO terms) covering a range of cell
processes and functions. Among all potential protein targets annotated on
the basis of the 11 GO Slim categories, we selected the 110 proteins with
the highest number of memberships per category. For the cancer pathways
panel, the same 1,100 proteins were annotated using a similar strategy, but
this time targeting relevant cancer pathways as described in the KEGG
pathway annotation database. For the neuro-oncology panel, we compiled ah subclusters 1 (orange) and 2 (green) encompassing the day-6 untreated cells
cells. Subclusters 1 and 4 primarily contain proliferationhigh cells. For the vector
NA (dashed vector lines) or protein (solid vector lines), correlating with each of
rrelation to each of the components.
iated with PC1 and PC2 from the PCA analysis shown in (A).
re identified by colors as described in (A). The y axis represent normalized Cq
ackground.
list of protein targets of interest for glioblastoma tumor biology by curating the
literature.
PEA Assays
Each PEA assay is generated by conjugating the 50 end of two different oligo-
nucleotides to a pair of antibodies forming a PEA A- and B-probe. The A-probe
is then hybridizedwith an oligonucleotide that is partially complementary to the
A-oligonucleotide and where the 30 end is complementary to 30 end of the con-
jugated B-oligonucleotide. The antibody pair can either be sourced from two
monoclonal antibodies detecting non-overlapping epitopes or from a poly-
clonal antibody raised against a peptide representing a large-as-possible frac-
tion of the target protein. The list of antibodies used in this study can be found
in Table S1. The oligonucleotides contain two different primer pair specific se-
quences that, when in proximity and extended, can be used for first universal
and then target specific PCR amplification.
Protein detection using PEA was performed as follows: 1 ml cell lysate was
mixed with 3 ml PEA probe mix. The mix contained 0.3 ml of each the PEA
A- and B-probes (final antibody-conjugate concentration 100 pM), 0.2 ml Incu-
bation Stabilizer (Olink Bioscience), and 2.1 ml Incubation Solution (Olink
Bioscience). Each 96-well plate included a negative control in triplicate (lysis
buffer only), two population controls (two 150-cell lysates sorted at the same
time as the single cells), and Olink Bioscience’s inter-plate control in triplicate
(Assarsson et al., 2014). The plate was briefly centrifuged, sealed, and incu-
bated overnight at 4C.
Following overnight incubation, plates were briefly spun down, and 96 ml of a
PEA probe extension mix was added to each well. The mix contained 0.2 ml
PCR Polymerase, 0.5 ml PEA Enzyme, and 10 ml PEA Solution (all Olink Biosci-
ence) and 85.3 ml molecular grade water. Plates were sealed, gently vortexed,
spun down, and then placed in a thermal cycler for the extension reaction
(50C, 20 min) and pre-amplification of extended PEA probes (or DNA reporter
molecules) via universal primers (95C, 5 min; (95C, 30 s; 54C, 1 min; and
60C, 1 min) 3 17.
The pre-amplified DNA reporter molecules from the multiplex detection re-
action were decoded and quantified using a Fluidigm 96.96 Dynamic Array In-
tegrated Fluidic Circuit on a Biomark HD system. 2.8 ml of each sample was
mixed with 5 ml Detection Solution, 0.071 ml Detection Enzyme, and 0.028 ml
PCR Polymerase (all Olink Bioscience) and 2.1 ml molecular grade water.
5 ml of each sample plus detection mix was loaded into a primed 96.96 Dy-
namic Array IFC (right inlets). 5 ml of each of the 96 primer pairs (Olink Biosci-
ence), designed to amplify individual target-specific DNA reporter sequences
generated in the PEA reactions, was also loaded in the Dynamic Array (left in-
lets). The chip was placed in Fluidigm’s IFC HX according to the manufac-
turer’s instructions and then run in Fluidigm’s Biomark with the following
settings (Gene Expression application, ROX passive reference, single-probe
assay with FAM-MGB probe) and protocol: thermal mix (50C, 120 s; 70C,
1,800 s; 25C, 600 s), hot start (95C, 300 s), and PCR cycling for 40 cycles
(95C, 15 s; 60C, 60 s).
Cell Lysis
Cells lysates were prepared with the following lysis buffer in order to maximize
recovery of both proteins and RNA: 1% NP-40, 0.1% Triton X-100, 0.1% sul-
fobetaine, 150 mMNaCl, 2U SUPERaseIN (Life Technologies), Protease Inhib-
itor Cocktail cOmplete mini (Roche), and Resuspension Buffer as supplied in
the CellsDirect One-Step qRT-PCR Kit (Life Technologies).
Cell Lysates for Assay Validation
Cell lysates were prepared from the cell lines MCF-7 (ATCC HTB-22) and
Hs578T (ATCC HTB-126), and from three early-passage glioblastoma cancer
stem cell cultures from the Uppsala University Human Glioma Cell Culture bio-
bank (U3013MG, U3017MG, and U3065MG; Xie et al., 2015). Briefly, defined
numbers of cells were flow sorted directly into lysis buffer (Figure S1) or lysed
in bulk at a concentration of 1,000 cells/ml. The lysates were aliquoted and kept
frozen at 80C until use. Lysates were diluted to contain the equivalent of
1,000, 100, 10, and 1 cell per aliquot. For PEA assays, controls included a
mix of recombinant antigens representing a subset of antibody targets (n =
60) and lysis buffer alone to calculate assay-specific background (data not
shown).CPEA Assay Validation
The cell lysates were screened with a total of 323 PEA assays against unique
targets. Each PEA assay was assessed for sensitivity, cross-reactivity, and
appropriate dose-response against cell lysates or recombinant antigens (Fig-
ure S1). Assays displaying single- or near-single-cell sensitivity, minimal
variation in replicates, and no evidence of cross-reactivity were chosen for
subsequent analysis of the U3035MG cells. The final panel included 79 PEA
assays plus four spike-in controls. The Olink Bioscience spike-in controls
included the two recombinant non-human proteins GFP and phycoerythrin
(Protein.SpikeinProteinI_CTRL and Protein.SpikeinProteinII_CTRL, respec-
tively) as incubation controls, an extension control, and a PCR or detection
control (Assarsson et al., 2014). The extension control is included to control
for intra-plate technical variation and was accordingly used to normalize the
real-time PCR measurements. See Figure S1 for pooled cell dilutions from
the final panel. The panel was annotated using the Molecular Signatures Data-
base (MSigDB) using curated gene sets KEGG and REACTOME as well as GO
gene sets (see Table S1 for details of the annotation).
Gene Expression Assay Validation
TaqMan Gene Expression assays were screened iteratively in multiplex, and
assays displaying high signals in negative controls or low sensitivity in dilution
series were excluded from subsequent testing. The final panel included 82 as-
says plus an External RNA Controls Consortium (ERCC) RNA spike-in control
(Life Technologies) (Table S1). The ERCC spike-in was read out by a targeted
TaqMan Expression assay (Table S1).
Cells for Analysis of BMP4 Treatment
The U3035MG cell line was isolated from a patient diagnosed with grade IV
glioblastoma at the University Hospital, Uppsala, Sweden, in accordance
with protocols approved by the regional ethical review board and following
written consent from the patient. Tumor tissue was dissociated using a scalpel
to first mince the tissue, followed by passage through a syringe with a 18G and
22G needle and incubation in a 1:1 mixture of Accutase (eBioscience) and Try-
pLE (Invitrogen) for 10min at 37C. The cells were washed twice in DMEM/F12
medium with centrifugation at 600 rpm for 8 min. The cells were cultured for
5–7 days as spheres on non-coated dishes and then transferred to laminin-
coated dishes to establish adherent monolayers. The cells were grown in
medium containing a 1:1 mix of Neurobasal (Invitrogen) and DMEM/F12 (Invi-
trogen) medium supplemented with N2 (Invitrogen), B27 (Invitrogen), 10 ng/ml
EGF (Peprotech), and 10 ng/ml FGF-2 (Peprotech).
For BMP4 treatment experiments, U3035MG (passage 8) cells were seeded
onto laminin-coated dishes at 1,000 cells/well in 24-well dishes, 3.3 3
104 cells/well in 60-mm dishes, or 1.5 3 104 cells/well in 35-mm dishes.
Approximately 48 hr after seeding the cells, the cell media was changed and
BMP4 (10 ng/ml) was added to the treatment wells. During the experiment,
the cell media was changed and new BMP4 was added on days 2 and 5.
The cells in the 35- or 60-mm dishes were used to set the gates for sorting,
and those in the 24-well dishes were either sorted and analyzed or counted
in triplicate using a hematocytometer (Neubauer improved cell counting cham-
ber). For the flow cytometry confirmatory experiments, U3035MG cells were
seeded 3.3 3 104 cells/well in 60-mm plates and treated with BMP4 as
described above. Before cell dissociation and fixation on day 6, cells were
pulsed with the proliferation marker EdU (10 mM, Life Technologies) for 1 hr.
Flow Cytometry and Cell Sorting
At the analyzed time points, single-cell suspensions of control and BMP4-
treated cells were prepared for sorting by FACS. Cells were washed once
with PBS and then dissociated from the culture dish using StemPro Accutase
(Life Technologies) for maximally 5 min at 37C. The dissociation agent was
diluted using cold PBS; the cells were centrifuged for 5 min at 1,000 rpm
and then gently resuspended in 400 ml cold PBS and sorted within 1 hr. Cells
were flow sorted into 96-well plates containing 2 ml lysis using the BD
FACSAria III. Two population controls of 150 cells/well were included on
each plate. Following sorting, plates were centrifuged, snap frozen, and stored
at 80C until processing.
For the flow cytometry confirmation experiments, cells were fixed with
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5% fetal bovine serum (FBS)/0.1% saponin/PBS solution for 30 min at room
temperature (RT). Cells were then probed with either a rabbit anti-TNC
(Abcam ab108930) or a rabbit anti-TUBB3 (Sigma, T2200) for 30 min at
RT, washed, and then probed with a donkey anti-rabbit Alexa 488 second-
ary antibody (Invitrogen A21206) for 30 min at RT. As a negative control,
cells were probed with only the anti-rabbit Alexa 488 secondary antibody.
Incorporation of EdU was resolved following the manufacturer’s protocol.
Following a wash step, the cells were resuspended in a 0.5% BSA/4 mM
EDTA/PBS solution. Cells were subsequently analyzed on the BD
FACSAria III.
Coefficient of Variation Analysis
To assess the precision with which proteins and transcripts could be
measured in lysates from half-cells, we sorted 40 single U3035MG, MCF-7,
or Hs587T cells for protein analysis and another 40 for RNA analysis. For
each single cell, we measured both halves either using TaqMan assays or
PEA assays. The CV% for each assay and single cell was calculated using
the mean and SD for each assay for each of the two halves of the 40 single
cells. In Figure 1C, the CV% was plotted for each PEA assay as a function
of the number of cells in which the PEA assay generated a detectable signal.
The cells used for this analysis were different from the cells sorted and
analyzed for BMP4 response.
cDNA Synthesis and Single-Cell qPCR
Thawed cell lysate plates were gently vortexed and centrifuged. 1 ml cell lysate
was transferred to 19 ml RT-PCR mix. The mix contained 13 Cells Direct
Reaction Mix and 0.5 ml Superscript III/Platinum Taq from the CellsDirect
One-Step qRT-PCR Kit, 2U SUPERaseIN (Life Technologies), 5 ml 0.23
TaqMan Gene Expression assay mix, and TE buffer (pH 8.0) (Life Technolo-
gies). cDNA was synthesized at 50C for 15 min, heated to 70C for 2 min,
and then incubated through 16 cycles of 95C for 15 s and 60C for 2 min.
The assay mix contained pre-mixed TaqMan Gene Expression Assays (n =
89) plus the ERCC RNA Spike-in Mix (dilution 1:1,000; Ambion). Amplified
cDNA was diluted 1:3 with TE buffer before qPCR analysis on the Fluidigm
BioMark HD System in a 96.96 Dynamic Array IFC, following the manufac-
turer’s instructions. After removal of 1 ml cell lysate for RNA expression anal-
ysis, 3 ml PEA probe mix was added to the remaining 1 ml half-cell lysate and
PEA was performed as described above.
Data QC
The RT-PCR output files from RNA assay determinations in the Fluidigm Bio-
Mark microfluidic real-time PCR instrument were processed to eliminate
(1) data points labeled as failed by Fluidigm’s Real-Time PCR analysis soft-
ware, (2) unreliable negative control rows with at least one non-failed value
for a non-ERCC assay, and (3) unreliable rows for which the value of the
ERCC controls was less than the lower inner fence value (Q1  1.5*IQR) or
greater than the upper inner fence value (Q3 + 1.5*IQR) of the ERCC distribu-
tion (0-hr control, n = 2 cells; day-6 control, n = 12 cells; day-6 BMP4, n = 3
cells). The remaining Ct values were normalized as follows: for each sample
(plate row), the Ct value of the ERCC was subtracted from the Ct values of
the analytes (yielding dCt values), and the resulting values were subtracted
from the difference between the LOD (set at 25) and the corresponding Ct
value of the ERCC (yielding ddCt values). All ddCt values less than zero
were set to zero, and the corresponding signals were deemed undetected.
Similarly, BioMark output files from protein determinations were processed
to eliminate (1) data points labeled as Failed in the QC step of the run, (2) un-
reliable NEGCTRL rows containing a non-failed value in a blank assaywell, and
(3) unreliable rows for which the value of the extension control (ExtCtl) was
smaller than the lower inner fence value (Q1  1.5*IQR) or greater than the up-
per inner fence value (Q3 + 1.5*IQR) of the ExtCtl distribution. The remaining Ct
values were normalized as follows: for each sample (plate row), the Ct value of
the ExtCtr was subtracted from the Ct value of the analyte (yielding dCt values),
and for each assay (plate column), the median of the three inter-plate control
(Assarsson et al., 2014) samples was subtracted from the resulting value
(yielding ddCt values). The inter-plate control is used to minimize inter-plate
variation for each individual assay. Then, for each assay, the ddCt values
were subtracted from a negative control background value computed as the388 Cell Reports 14, 380–389, January 12, 2016 ª2016 The Authorsmean 2*SD of at least twoNEGCTRL values. This ensures that observed sig-
nals for each assay in the presence of a cell are at least 2 SDs away from any
signals observed in the absence of any antigen. All resulting values below zero
were set to zero, and the signal was deemed undetected.
For both RNA and protein plates, single cells were culled by adding the re-
sulting values across all assays, computing the median and SD of the resulting
distribution, and eliminating single-cell samples for which the total values were
smaller than the median 3*SD or greater than the median + 3*SD. For the re-
maining single-cell samples, the normalized values for each column (i.e., ana-
lyte) were transformed into Z scores by subtracting the median and dividing by
the SD.
Statistical Analysis
The combined Z scores for RNA and protein assays were used as input for a
PCA performed using the FactoMineR package in R. Variables contributing
to each of the first two components were selected based on the significance
(p < 0.001) of their association with each component. Hierarchical clustering
was performed in R using Euclidean distances and Ward’s clustering
criterion.
For the correlation analysis, data were first filtered to include only matched
RNA/protein pairs that fulfilled our QC criteria in a total of 130 cells (69 cells
treated with BMP4 [+] and 62 untreated controls []). The data were subse-
quently organized into two matrices (rows = analytes, columns = cells) for
RNA and for protein. The data were row-standardized by Z score transforma-
tion for each analyte. First, we estimated the first two principal components
from the data. To classify treated (+) from untreated () cells, we used Linear
Discriminant Analysis (LDA; James et al., 2013). In a leave-one-out cross-vali-
dation, we systematically excluded each of the 130 cells from the data and
fitted an LDA model from the remaining 129 cells (MATLAB fitcdiscr function).
From the posterior LDA score assigned to the excluded samples, we calcu-
lated an ROC curve in which x = 1  specificity and y = sensitivity.
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